NEW YORK (

TheStreet

) --

Prana Biotechnology

(PRAN)

was skyrocketing for the second straight day Tuesday after it published data in the science journal

PLoS One

on the ability of its drug PBT2 to restore cognition in mice stricken by Alzheimer's disease. The stock was soaring 43% to $3.90. Volumes jumped to nearly 22 million in noon trading. Volumes have typically been under 300,000 in the last three months.

Adeona Pharmaceuticals

( AEN) was another pharmaceutical company gaining on unusual volumes, climbing 18.8% to $1.75. There were no company announcements driving the move, although Adeona is developing a clinical-stage oral, gastro-retentive and sustained-release medical food candidate for the dietary management of Alzheimer's.

Rare earth stocks were gaining after China rare earth exports data showed prices were more than double last year's average. China's exports of rare earth metals burst through the $100,000-per-ton mark for the first time in February, up almost nine-fold from a year before, while the volume of trade stayed far below historical averages, according to a

Reuters

report. The stock of

Rare Element Resources

(REE)

was jumping 13% to $11.72.

Shares of

China GengSheng Minerals

(CHGS)

and

China Shen Zhou

(SHZ)

gained 32% and 19% respectively.

Avalon Rare Metals

(AVL)

and

Qiao Xing Universal Resources

( XING) also gained.

Chinese internet stock

Dangdang

(DANG)

was gaining 8.7% to $20.56 after Piper Jaffray upgraded the stock to overweight from neutral but lowered its price target to $25 from $30 previously.

Shares of online gaming software company

Cryptologic

( CRYP) were surging 17% to $1.28 after its fourth-quarter loss narrowed to 6 cents a share from $1.98.

--Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here:

Shanthi Bharatwaj

.

>To follow the writer on Twitter, go to

http://twitter.com/shavenk

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.